ABG
WHWK

Ally Bridge Group’s Whitehawk Therapeutics WHWK Stock Holding History

Ally Bridge Group’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.75M Hold
817,939
– – 3.31% 8
2026
Q1 		$2.82M Hold
817,939
– – 2.28% 22
2025
Q4 		$1.98M Hold
817,939
– – 2.06% 17
2025
Q3 		$1.55M Hold
817,939
– – 0.95% 22
2025
Q2 		$1.53M Hold
817,939
– – 1.27% 21
2025
Q1 		$1.46M Hold
817,939
– – 1.31% 24
2024
Q4 		$2.58M Buy
+817,939
New +$1.85M 2.21% 20
2023
Q1 		– Sell
-632,997
Closed -$8.12M – 39
2022
Q4 		$8.12M Buy
632,997
+508,372
+408% +$6.64M 7.9% 2
2022
Q3 		$1.76M Buy
+124,625
New +$1.64M 1.16% 27

Other funds holding WHWK

YF
Yu Fan $108M AUM 137.54% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $136M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ally Bridge Group's WHWK Position: Q2 2026 in Review

Ally Bridge Group held its Whitehawk Therapeutics (WHWK) position steady in Q2 2026 at 817,939 shares worth $3.75M. The position accounts for 3.31% of the portfolio, ranked #8.

Ally Bridge Group first reported a position in WHWK in Q3 2022 and has held it in 9 quarters since. The position peaked at $8.12M in Q4 2022. 78 funds tracked by Wall St. Rank hold WHWK as of Q2 2026.

  • Ally Bridge Group held 817,939 shares of Whitehawk Therapeutics worth $3.75M as of Q2 2026.
  • Ally Bridge Group left its Whitehawk Therapeutics share count unchanged in Q2 2026.
  • Whitehawk Therapeutics made up 3.31% of Ally Bridge Group's portfolio in Q2 2026, its #8 holding.
  • Ally Bridge Group first reported a position in Whitehawk Therapeutics in Q3 2022 and has held it in 9 quarters since.
  • Ally Bridge Group's Whitehawk Therapeutics position peaked at $8.12M in Q4 2022.
  • 78 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q2 2026.

Based on Ally Bridge Group's 13F filing for Q2 2026, filed 14 Aug 2026.